IP Library Granted Patent US 8,980,629
Granted Patent B2
US 8,980,629 · App. 13/975,238 · Granted Mar 17, 2015

Compounds that modulate intracellular calcium

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,980,629
App. No.
13/975,238
Granted
Mar 17, 2015
Kind
B2
Abstract

Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity.

Claims (33)

1. A compound having the structure of Formula (VIA):

wherein:

R′ 1 is

L 2 is —NH—C(═O)—, or —C(═O)NH—;

X is N;

Y is CR 9 ;

R 2 is aryl or heteroaryl; wherein aryl or heteroaryl is optionally substituted with at least one R 3 ;

R 3 is independently selected from F, Cl, Br, I, —CN, —NO 2 , —OH, —CF 3 , —OCF 3 , —OR 5 , C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 1 -C 6 heteroalkyl, C 1 -C 6 haloalkyl, C 2 -C 8 heterocycloalkyl, optionally substituted aryl, optionally substituted O-aryl, optionally substituted heteroaryl,

n is an integer selected from 0-2;

R 9 is independently selected from H, D, halogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, —OR 5 , —OCF 3 , C 1 -C 6 carbonylalkyl, or —CF 3 ; or two R 9 attached to the same carbon atom form an oxetane ring;

R 10 is selected from halogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, —OR 5 , —OCF 3 , C 1 -C 6 carbonylalkyl, or —CF 3 ;

R 5 is independently selected from H, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 8 cycloalkyl, phenyl, and benzyl;

or a pharmaceutically acceptable salt, or pharmaceutically acceptable solvate thereof.

2. The compound of claim 1 wherein

L 2 is —NH—C(═O)—;

Y is CH; and

R 2 is aryl substituted with at least one R 3 .

3. The compound of claim 2 wherein R 2 is phenyl substituted with at least one R 3 .

4. The compound of claim 3 wherein R 2 is substituted with at least one R 3 selected from Cl, Br, F, I, CF 3 , and C 1 -C 6 alkyl.

5. The compound of claim 4 wherein R 2 is substituted with at least one R 3 selected from Cl, F, and CH 3 .

6. The compound of claim 5 wherein R 2 is substituted with at least one F.

7. The compound of claim 6 wherein at least one R 9 is a halogen.

8. The compound of claim 7 wherein at least one R 9 is a F.

9. The compound of claim 8 wherein R′ 1 is

and n is 0.

10. The compound of claim 9 wherein R 10 is a halogen or C 1 -C 6 alkyl.

11. The compound of claim 10 wherein R 10 is Cl.

12. The compound of claim 10 wherein R 10 is —CH 3 .

13. The compound of claim 10 wherein R 10 is —CH 2 CH 3 .

14. The compound of claim 11 wherein R 2 is substituted with two R 3 , wherein one R 3 is F and one R 3 is CH 3 .

15. The compound of claim 12 wherein R 2 is substituted with two R 3 , wherein one R 3 is F and one R 3 is Cl.

16. The compound of claim 12 wherein R 2 is substituted with three R 3 , wherein each R 3 is F.

17. A pharmaceutical composition comprising a pharmaceutically acceptable diluent, excipient or binder, and a compound of claim 1 or pharmaceutically acceptable salt, pharmaceutically acceptable prodrug, or pharmaceutically acceptable solvate thereof.

Assignments (2)
SECURITY INTEREST Recorded Mar 4, 2025
From: CALCIMEDICA, INC.
To: AVENUE CAPITAL MANAGEMENT II, L.P.
Reel/Frame 070394/0314 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 5, 2013
From: WHITTEN, JEFFREY P.; PEI, YAZHONG; CAO, JIANGUO; WANG, ZHIJUN; ROGERS, EVAN; DYCK, BRIAN; GREY, JONATHAN
To: CALCIMEDICA, INC.
Reel/Frame 031147/0565 →